One such histone deacetylase, namely, HDAC8, is implicated in the invasion and metastasis abilities of cancer; meanwhile, selective inhibition of HDAC8 serves as a therapeutic agent in various malignancies, including breast cancer, hepatocellular carcinoma, and CRC [9–14]. This evidence concerns the gene HDAC8 and breast carcinoma.